Colinz Lab Peer Comparison

BSE: 531210

₹69.25

₹-0.75 (-1.07%)

As on 30-Oct-2026IST

Market cap

₹17 Cr

Revenue (TTM)

₹6 Cr

P/E Ratio

6.3

P/B Ratio

1.4

Div. Yield

0 %

Edit

	Colinz Lab	Acutaas Chemicals	Piramal Pharma	Onesource Specialty Pharma	Syngene Intl
Market cap (₹ Cr)	17	32,770	31,826	17,926	16,252
Revenue (₹ Cr)	6	1,593	9,779	1,684	3,522
Net Profit (₹ Cr)	2.78	438.64	-270.51	-1.62	186.10
Net Margin (%)	42.90	27.16	-2.71	-0.10	5.15
RoE (%)	4.34	25.02	-2.55	0.22	4.93
Price to Earnings	6.27	74.62	--	--	87.33
Price-To-Book	1.37	17.64	3.91	3.03	3.34

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Colinz Lab	Acutaas Chemicals	Piramal Pharma	Onesource Specialty Pharma	Syngene Intl
Operating Revenue	5.97	1,592.52	9,778.62	1,683.82	3,522.30
Total Income	6.48	1,615.23	9,993.26	1,695.30	3,613.20
Total Expenditure	5.64	969.32	8,578.44	1,287.94	2,771.50
EBITDA	0.34	623.20	1,200.18	395.88	750.80
Depreciation	0.14	41.96	887.82	288.26	449.10
EBIT	0.20	581.24	312.36	107.62	301.70
Interest	0.05	4.21	347.94	126.12	43.60
Other Income	0.51	22.71	214.64	11.47	90.90
Exceptional Items	2.76	0.00	-216.88	-13.12	-96.80
Profit before Tax	3.43	599.74	-37.82	-20.14	252.20
Provision for Tax	0.65	161.10	232.69	-18.52	66.10
Profit after Tax	2.78	438.64	-270.51	-1.62	186.10

Liabilities (₹ Cr)

	Colinz Lab	Acutaas Chemicals	Piramal Pharma	Onesource Specialty Pharma	Syngene Intl
Shareholder's Funds	12.71	1,857.45	8,142.24	5,920.89	4,858.80
Minority Interest	0.00	0.51	0.55	0.00	0.00
Non-Current Liabilities	0.19	47.15	5,213.99	1,001.58	616.80
Current Liabilities	1.83	253.37	5,158.51	1,663.61	1,182.90
Total Liabilities	12.78	1,983.96	17,723.32	8,222.05	7,054.70

Assets (₹ Cr)

	Colinz Lab	Acutaas Chemicals	Piramal Pharma	Onesource Specialty Pharma	Syngene Intl
Non-Current Assets	1.69	1,132.12	10,687.30	6,364.60	3,950.40
Current Assets	13.02	1,012.00	7,253.65	1,697.49	1,948.10
Total Assets	12.78	1,983.96	17,723.32	8,222.05	7,054.70
Total Debt*	0.39	26.49	5,495.48	1,276.30	9.40
Net Current Assets	11.19	758.64	2,095.14	33.87	765.20
Contingent Liabilities	--	17.25	95.72	1,287.25	536.50

Cashflow (₹ Cr)

	Colinz Lab	Acutaas Chemicals	Piramal Pharma	Onesource Specialty Pharma	Syngene Intl
Cash From Operating Activities	2.54	292.17	1,652.60	8.52	915.20
Cash Flow from Investing Activities	0.01	-265.94	-826.03	-494.98	-860.40
Cash from Financing Activities	0.43	4.10	-38.98	359.44	-215.00
Net Cash Inflow / Outflow	2.98	30.33	787.59	-127.02	-160.20

Ratios

Profitability Ratios

	Colinz Lab	Acutaas Chemicals	Piramal Pharma	Onesource Specialty Pharma	Syngene Intl
ROCE (%)	7.16	32.42	1.24	0.44	9.48
ROE (%)	4.34	25.02	-2.55	0.22	4.93
ROA (%)	20.71	22.40	-1.56	-0.02	2.82
EBIT Margin (%)	3.37	36.50	3.19	6.39	8.57
Net Margin (%)	42.90	27.16	-2.71	-0.10	5.15
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Colinz Lab	Acutaas Chemicals	Piramal Pharma	Onesource Specialty Pharma	Syngene Intl
Revenue Growth (%)	1.74	45.18	9.43	10.66	-5.99
EBIT Growth (%)	-13.36	115.51	-3.72	-55.98	-48.77
Net Profit Growth (%)	501.95	95.80	-199.34	-103.99	-60.25
EPS Growth (%)	6.97	63.29	-410.28	-91.16	-49.04
Book Value Growth (%)	6.00	26.03	0.33	-0.75	2.11

Valuation Ratios

	Colinz Lab	Acutaas Chemicals	Piramal Pharma	Onesource Specialty Pharma	Syngene Intl
Price / Earnings	35.30	74.62	-153.04	1,397.87	67.94
Price / Book Value	1.37	17.64	3.91	3.03	3.34
Dividend Yield (%)	0.00	0.06	0.00	0.00	0.31
EV/EBITDA	27.61	52.27	29.97	48.25	19.94
Market Cap (₹ Cr)	11.21	20,944.75	18,108.89	16,876.12	15,723.10

Solvency Ratios

	Colinz Lab	Acutaas Chemicals	Piramal Pharma	Onesource Specialty Pharma	Syngene Intl
Debt to Equity	0.00	0.02	0.55	0.10	0.00
Short term debt to equity ratio	0.04	0.00	0.09	0.10	0.00
Current Ratio	7.10	3.99	1.41	1.02	1.65
Quick Ratio	6.65	2.89	0.77	0.75	1.51
Interest Coverage	77.20	143.52	0.89	0.84	6.78

Operating Efficiency Ratios

	Colinz Lab	Acutaas Chemicals	Piramal Pharma	Onesource Specialty Pharma	Syngene Intl
Debtors to sales (%)	15.22	22.50	23.05	61.34	10.94
Asset Turnover	0.44	0.81	0.56	0.20	0.53
Receivable days	44.49	88.98	78.20	140.79	50.33
Inventory Days	44.15	56.04	93.30	75.94	14.43
Payable days	98.78	99.95	226.14	225.76	17,487.50
Cash Conversion Cycle	-10.13	45.07	-54.64	-9.03	-17,422.74

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly